Ami A Shah1, Antony Rosen2, Laura K Hummers2, Betty J May3, Alpana Kaushiva3, Richard B S Roden4, Deborah K Armstrong5, Fredrick M Wigley2, Livia Casciola-Rosen2, Kala Visvanathan6. 1. Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ami.shah@jhmi.edu. 2. Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Division of Medical Oncology, Department of Medicine, Johns Hopkins University School of Medicine Baltimore MD, USA. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore; and Division of Medical Oncology, Department of Medicine, Johns Hopkins University School of Medicine Baltimore MD, USA. kvisvan1@jhu.edu.
Abstract
OBJECTIVES: Systemic sclerosis (scleroderma) and dermatomyositis are two prototypic autoimmune diseases that are strongly associated with malignancy. While specific autoantibodies in these diseases are markers of an increased risk of cancer at scleroderma and dermatomyositis onset, it is not known whether these autoantibodies are biomarkers of cancer risk in patients without rheumatic disease. METHODS: In a matched case-control study of women without rheumatic disease, identified from a familial breast cancer cohort, 50 breast cancer cases and 50 controls were assayed for 3 autoantibodies that are known markers of cancer-associated scleroderma and dermatomyositis: anti-RNA polymerase III, anti-NXP2, and anti-TIF1γ. RESULTS: No subject had moderate or strong autoantibody positivity. Eleven women were borderline positive for at least one autoantibody. The prevalence of borderline autoantibody positivity did not differ between cases and controls. CONCLUSIONS: Our results suggest that scleroderma and dermatomyositis autoantibodies are cancer biomarkers only in patients with clinical manifestations of specific rheumatic diseases and are unlikely to improve risk stratification for cancer in the general population. However, prospective studies are needed to examine whether scleroderma and dermatomyositis autoantibodies are markers of malignancy in other cancer types.
OBJECTIVES:Systemic sclerosis (scleroderma) and dermatomyositis are two prototypic autoimmune diseases that are strongly associated with malignancy. While specific autoantibodies in these diseases are markers of an increased risk of cancer at scleroderma and dermatomyositis onset, it is not known whether these autoantibodies are biomarkers of cancer risk in patients without rheumatic disease. METHODS: In a matched case-control study of women without rheumatic disease, identified from a familial breast cancer cohort, 50 breast cancer cases and 50 controls were assayed for 3 autoantibodies that are known markers of cancer-associated scleroderma and dermatomyositis: anti-RNA polymerase III, anti-NXP2, and anti-TIF1γ. RESULTS: No subject had moderate or strong autoantibody positivity. Eleven women were borderline positive for at least one autoantibody. The prevalence of borderline autoantibody positivity did not differ between cases and controls. CONCLUSIONS: Our results suggest that scleroderma and dermatomyositis autoantibodies are cancer biomarkers only in patients with clinical manifestations of specific rheumatic diseases and are unlikely to improve risk stratification for cancer in the general population. However, prospective studies are needed to examine whether scleroderma and dermatomyositis autoantibodies are markers of malignancy in other cancer types.
Authors: Amy L Gross; Betty J May; Jennifer E Axilbund; Deborah K Armstrong; Richard B S Roden; Kala Visvanathan Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-15 Impact factor: 4.254
Authors: Ami A Shah; Laura K Hummers; Livia Casciola-Rosen; Kala Visvanathan; Antony Rosen; Fredrick M Wigley Journal: Arthritis Rheumatol Date: 2015-04 Impact factor: 10.995
Authors: David F Fiorentino; Lorinda S Chung; Lisa Christopher-Stine; Lisa Zaba; Shufeng Li; Andrew L Mammen; Antony Rosen; Livia Casciola-Rosen Journal: Arthritis Rheum Date: 2013-11
Authors: Pia Moinzadeh; Carmen Fonseca; Martin Hellmich; Ami A Shah; Cecilia Chighizola; Christopher P Denton; Voon H Ong Journal: Arthritis Res Ther Date: 2014-02-14 Impact factor: 5.156
Authors: Zoe E Betteridge; Lynsey Priest; Robert G Cooper; Neil J McHugh; Fiona Blackhall; Janine A Lamb Journal: Arthritis Res Ther Date: 2018-08-09 Impact factor: 5.156